Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review

被引：13

作者：

Caron, Benedicte ^{[1
,2
]}

Jairath, Vipul ^{[3
,4
,5
]}

D'Amico, Ferdinando ^{[6
,7
,8
]}

Paridaens, Kristine ^{[9
]}

Magro, Fernando ^{[10
,11
,12
]}

Danese, Silvio ^{[6
,7
]}

Peyrin-Biroulet, Laurent ^{[1
,2
]}

机构：

[1] Univ Lorraine, Nancy Univ Hosp, Dept Gastroenterol, 1 Allee Morvan, F-54511 Nancy, France

[2] Univ Lorraine, Nancy Univ Hosp, INSERM, NGERE U1256, 1 Allee Morvan, F-54511 Nancy, France

[3] Western Univ, Dept Med, London, ON, Canada

[4] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada

[5] Alimentiv Inc, London, ON, Canada

[6] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy

[7] Univ Vita Salute San Raffaele Milano, Milan, Italy

[8] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[9] Ferring Int Ctr, St Prex, Switzerland

[10] Univ Porto, Fac Med, Unit Pharmacol & Therapeut, Dept Biomed, Porto, Portugal

[11] Sao Joao Univ Hosp Ctr CHUSJ, Dept Clin Pharmacol, Porto, Portugal

[12] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal

来源：

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL | 2022年 / 10卷 / 08期

关键词：

definition; mild; moderate; predictive factor; ulcerative colitis; RELEASE ORAL MESALAMINE; INFLAMMATORY-BOWEL-DISEASE; 400 MG TABLETS; DOUBLE-BLIND; BECLOMETHASONE DIPROPIONATE; MESALAZINE TABLETS; BUDESONIDE FOAM; MMX MESALAZINE; DOUBLE-DUMMY; EFFICACY;

D O I：

10.1002/ueg2.12283

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We performed a systematic review to investigate the definition of mild to moderate active ulcerative colitis (UC), and to describe predictors of good response to treatment in clinical trials assessing 5-ASA and/or budesonide. Thirty-nine randomized controlled trials were included. The UC Disease Activity Index (UCDAI) was the most frequent score used for defining mild to moderate active UC (16 studies, 41%), followed by Clinical Activity Index in 11 studies (28.2%). Four different cut-offs were used to define mild to moderate active UC using the UCDAI. The most frequently reported predictors of good response to treatment was a mild and moderate disease activity. There is heterogeneity in the definition of mild to moderate active UC in randomized clinical trials. A standardized definition of mild to moderate active UC used for inclusion of patients in clinical trials is needed.

引用

页码：854 / 867

页数：14

共 59 条

[1] Clinical Trial: A Novel High-dose 1 g Mesalamine Suppository (Salofalk) Once Daily Is as Efficacious as a 500-mg Suppository Thrice Daily in Active Ulcerative Proctitis [J].

Andus, Tilo ;

Kocjan, Andreas ;

Mueser, Moritz ;

Baranovsky, Andrey ;

Mikhailova, Tatyana L. ;

Zvyagintseva, Tatyana D. ;

Dorofeyev, Andrey E. ;

Lozynskyy, Yurii S. ;

Cascorbi, Ingolf ;

Stolte, Manfred ;

Vieth, Michael ;

Dilger, Karin ;

Mohrbacher, Ralf ;

Greinwald, Roland .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) :1947-1956

[2] Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis:: A multicenter, randomized, double-blind study [J].

Biancone, L. ;

Gionchetti, P. ;

Blanco, G. Del Vecchio ;

Orlando, A. ;

Annese, V. ;

Papi, C. ;

Sostegni, R. ;

D'Inca, R. ;

Petruzziello, C. ;

Casa, A. ;

Sica, G. ;

Calabrese, E. ;

Campieri, M. ;

Pallone, F. .

DIGESTIVE AND LIVER DISEASE, 2007, 39 (04) :329-337

[3] Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies [J].

Bosworth, Brian P. ;

Sandborn, William J. ;

Rubin, David T. ;

Harper, Joseph R. .

INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) :1881-1886

[4]

Colitis U, CLIN TRIAL ENDPOINTS

[5] Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis [J].

Cortot, Antoine ;

Maetz, Denis ;

Degoutte, Eric ;

Delette, Olivier ;

Meunier, Pierre ;

Tan, Gie ;

Cazals, Jean-Brice ;

Dewit, Olivier ;

Hebuterne, Xavier ;

Beorchia, Sylvain ;

Grunberg, Bernard ;

Leprince, Eric ;

D'Haens, Geert ;

Forestier, Sylvie ;

Idier, Isabelle ;

Lemann, Marc .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (12) :3106-3114

[6] Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study [J].

D'Haens, G. ;

Hommes, D. ;

Engels, L. ;

Baert, F. ;

Van der Waaij, L. ;

Connor, P. ;

Ramage, J. ;

Dewit, O. ;

Palmen, M. ;

Stephenson, D. ;

Joseph, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (07) :1087-1097

[7] Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis [J].

D'Haens, G. R. ;

Sandborn, W. J. ;

Zou, G. ;

Stitt, L. W. ;

Rutgeerts, P. J. ;

Gilgen, D. ;

Jairath, V. ;

Hindryckx, P. ;

Shackelton, L. M. ;

Vandervoort, M. K. ;

Parker, C. E. ;

Muller, C. ;

Pai, R. K. ;

Levchenko, O. ;

Marakhouski, Y. ;

Horynski, M. ;

Mikhailova, E. ;

Kharchenko, N. ;

Pimanov, S. ;

Feagan, B. G. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (03) :292-302

[8] Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis [J].

D'Haens, G. R. ;

Kovacs, A. ;

Vergauwe, P. ;

Nagy, F. ;

Molnar, T. ;

Bouhnik, Y. ;

Weiss, W. ;

Brunner, H. ;

Lavergne-Slove, A. ;

Binelli, D. ;

Di Stefano, A. F. D. ;

Marteau, P. .

JOURNAL OF CROHNS & COLITIS, 2010, 4 (02) :153-160

[9] A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis [J].

D'Haens, Geert ;

Sandborn, William J. ;

Feagan, Brian G. ;

Geboes, Karel ;

Hanauer, Stephen B. ;

Irvine, E. Jan ;

Lemann, Marc ;

Marteau, Philippe ;

Rutgeerts, Paul ;

Scholmerich, Jurgen ;

Sutherland, Lloyd R. .

GASTROENTEROLOGY, 2007, 132 (02) :763-786

[10] Positioning Therapies in Ulcerative Colitis [J].

Danese, Silvio ;

Fiorino, Gionata ;

Peyrin-Biroulet, Laurent .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (06) :1280-+

← 1 2 3 4 5 6 →